Amazon.com, Nvidia, Tesla, and the rest of the Magnificent Seven stocks jump as the U.S. and China reach an agreement to ...

Injected weight-loss drugs Wegovy, from Novo Nordisk, and Eli Lilly's Zepbound have U.S. list prices of over $1,000 a month.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Have you assessed how the international operations of Eli Lilly (LLY) performed in the quarter ended March 2025? For this drugmaker, possessing an expansive global footprint, parsing the trends of ...

The US is the biggest market for prescription drugs, accounting for roughly $600bn of annual sales out of a global $1tn or so ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an investigational GLP-1 weight loss candidate. The stock has not performed well ...

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

Health-care companies rose sharply after President Trump signed an executive order designed to lower what Americans pay for prescription drugs that offered pharmaceutical companies room for ...